Cited 20 times in
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.